Electroacupuncture pretreatment attenuates cerebral ischemic injury through α7 nicotinic acetylcholine receptor-mediated inhibition of high-mobility group box 1 release in rats

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Wang, Qiang ^a   Wang, Feng ^a   Li, Xin ^a   Yang, Qianzi ^a   Li, Xuying ^a   Xu, Ning ^a   Huang, Yi ^a   Zhang, Qiaomei ^a   Gou, Xingchun ^a   Chen, Shaoyang ^a   Xiong, Lize ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral ischemia; Electroacupuncture; High mobility group box 1; Pretreatment; 7 nicotinic acetylcholine receptor

Indexed keywords

ALPHA BUNGAROTOXIN; BUNGAROTOXIN RECEPTOR; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; N (3 QUINUCLIDINYL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; OXYGEN; BUNGAROTOXIN; DIAGNOSTIC AGENT; ENOLASE; FUSED HETEROCYCLIC RINGS; LACTATE DEHYDROGENASE; N (1 AZABICYCLO(2.2.2)OCT 3 YL)FURO(2,3 C)PYRIDINE 5 CARBOXAMIDE; N-(1-AZABICYCLO(2.2.2)OCT-3-YL)FURO(2,3-C)PYRIDINE-5-CARBOXAMIDE; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; QUINUCLIDINE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN LEVEL; BRAIN NERVE CELL; COGNITION; CONTROLLED STUDY; ELECTROACUPUNCTURE; ENZYME REPRESSION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PREMEDICATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RAT; REPERFUSION; THERAPY EFFECT; TREATMENT OUTCOME; ANIMAL; ANIMAL EMBRYO; ANOXIA; BRAIN CORTEX; BRAIN INFARCTION; BRAIN INJURY; CELL CULTURE; CEREBRAL ARTERY DISEASE; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; NERVE CELL; NICK END LABELING; NONPARAMETRIC TEST; PHYSIOLOGY; PROTEIN BINDING; SPRAGUE DAWLEY RAT;

ANIMALS; ANOXIA; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN INJURIES; BUNGAROTOXINS; CELLS, CULTURED; CEREBRAL CORTEX; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; ELECTROACUPUNCTURE; EMBRYO, MAMMALIAN; GENE EXPRESSION REGULATION; GLUCOSE; HMGB1 PROTEIN; IN SITU NICK-END LABELING; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENTRICULAR; L-LACTATE DEHYDROGENASE; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHOPYRUVATE HYDRATASE; PROTEIN BINDING; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; STATISTICS, NONPARAMETRIC; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84856101627     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-24     Document Type: Article

References (37)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008, 371:1612-1623. 10.1016/S0140-6736(08)60694-7, 18468545.
2. Dirnagl U, Becker K, Meisel A. Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol 2009, 8:398-412. 10.1016/S1474-4422(09)70054-7, 2668955, 19296922.
3. Wang Q, Xiong L, Chen S, Liu Y, Zhu X. Rapid tolerance to focal cerebral ischemia in rats is induced by preconditioning with electroacupuncture: window of protection and the role of adenosine. Neurosci Lett 2005, 381:158-162. 10.1016/j.neulet.2005.02.019, 15882809.
4. Wang Q, Peng Y, Chen S, Gou X, Hu B, Du J, Lu Y, Xiong L. Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system. Stroke 2009, 40:2157-2164. 10.1161/STROKEAHA.108.541490, 19372445.
5. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010, 67:181-198. 10.1016/j.neuron.2010.07.002, 2957363, 20670828.
6. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience 2009, 158:1122-1132. 10.1016/j.neuroscience.2008.09.009, 18848864.
7. McColl BW, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neuroscience 2009, 158:1049-1061. 10.1016/j.neuroscience.2008.08.019, 18789376.
8. Gallowitsch-Puerta M, Pavlov VA. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci 2007, 80:2325-2329. 10.1016/j.lfs.2007.01.002, 2921074, 17289087.
9. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Yang H, Ulloa L, Al-Abed Y, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388. 10.1038/nature01339, 12508119.
10. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Metz C, Miller EJ, Tracey KJ, Ulloa L. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10:1216-1221. 10.1038/nm1124, 15502843.
11. Kim JB, Lim CM, Yu YM, Lee JK. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 2008, 86:1125-1131. 10.1002/jnr.21555, 17975839.
12. Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI, Salomone S, Moskowitz MA. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008, 28:927-938. 10.1038/sj.jcbfm.9600582, 18000511.
13. Yang QW, Wang JZ, Li JC, Zhou Y, Zhong Q, Lu FL, Xiang J. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 2010, 30:243-254. 10.1038/jcbfm.2009.202, 2949127, 19794402.
14. Kavoussi B, Ross BE. The neuroimmune basis of anti-inflammatory acupuncture. Integr Cancer Ther 2007, 6:251-257. 10.1177/1534735407305892, 17761638.
15. Liu XY, Zhou HF, Pan YL, Liang XB, Niu DB, Xue B, Li FQ, He QH, Wang XH, Wang XM. Electro-acupuncture stimulation protects dopaminergic neurons from inflammation-mediated damage in medial forebrain bundle-transected rats. Exp Neurol 2004, 189:189-196. 10.1016/j.expneurol.2004.05.028, 15296849.
16. Yang EJ, Jiang JH, Lee SM, Hwang HS, Lee MS, Choi SM. Electroacupuncture reduces neuroinflammatory responses in symptomatic amyotrophic lateral sclerosis model. J Neuroimmunol 2010, 223:84-91. 10.1016/j.jneuroim.2010.04.005, 20460191.
17. Kempsill FE, Pratt JA. Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitization to the locomotor stimulant effects of nicotine. Br J Pharmacol 2000, 131:997-1003. 10.1038/sj.bjp.0703560, 1572401, 11053222.
18. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J Med Chem 2006, 49:4425-4436. 10.1021/jm0602413, 16821801.
19. Wang Q, Gou X, Xiong L, Jin W, Chen S, Hou L, Xu L. Trans-activator of transcription-mediated delivery of NEP1-40 protein into brain has a neuroprotective effect against focal cerebral ischemic injury via inhibition of neuronal apoptosis. Anesthesiology 2008, 108:1071-1080. 10.1097/ALN.0b013e318173f66b, 18497608.
20. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995, 26:627-634. discussion 635, 10.1161/01.STR.26.4.627, 7709410.
21. Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417:941-944. 10.1038/nature00867, 12068310.
22. Ashwal S, Tone B, Tian HR, Cole DJ, Pearce WJ. Core and penumbral nitric oxide synthase activity during cerebral ischemia and reperfusion. Stroke 1998, 29:1037-1046. discussion 1047, 10.1161/01.STR.29.5.1037, 9596255.
23. Lei B, Popp S, Capuano-Waters C, Cottrell JE, Kass IS. Lidocaine attenuates apoptosis in the ischemic penumbra and reduces infarct size after transient focal cerebral ischemia in rats. Neuroscience 2004, 125:691-701. 10.1016/j.neuroscience.2004.02.034, 15099683.
24. Wang Q, Gou X, Jin W, Xiong L, Hou L, Chen S, Zhang H, Zhu X, Xu L. TAT-mediated protein transduction of Nogo extracellular peptide 1-40 and its biological activity. Cell Mol Neurobiol 2009, 29:97-108. 10.1007/s10571-008-9301-2, 18758939.
25. Li XD, Buccafusco JJ. Effect of beta-amyloid peptide 1-42 on the cytoprotective action mediated by alpha7 nicotinic acetylcholine receptors in growth factor-deprived differentiated PC-12 cells. J Pharmacol Exp Ther 2003, 307:670-675. 10.1124/jpet.103.053785, 12970390.
26. Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, Yamamoto N, Kihara T, et al. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J Neurosci Res 2009, 87:576-585. 10.1002/jnr.21869, 18803299.
27. Aki HS, Fujita M, Yamashita S, Fujimoto K, Kumagai K, Tsuruta R, Kasaoka S, Aoki T, Nanba M, Murata H, et al. Elevation of jugular venous superoxide anion radical is associated with early inflammation, oxidative stress, and endothelial injury in forebrain ischemia-reperfusion rats. Brain Res 2009, 1292:180-190.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
29. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007, 184:53-68. 10.1016/j.jneuroim.2006.11.014, 1868538, 17188755.
30. Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med 2009, 265:663-679. 10.1111/j.1365-2796.2009.02098.x, 19493060.
31. van Rensburg R, Errington DR, Ennaceur A, Lees G, Obrenovitch TP, Chazot PL. A new model for the study of high-K(+)-induced preconditioning in cultured neurones: role of N-methyl-d-aspartate and alpha7-nicotinic acetylcholine receptors. J Neurosci Methods 2009, 177:311-316. 10.1016/j.jneumeth.2008.10.012, 19007816.
32. Egea J, Rosa AO, Sobrado M, Gandia L, Lopez MG, Garcia AG. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. Neuroscience 2007, 145:866-872. 10.1016/j.neuroscience.2006.12.036, 17291692.
33. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25:571-574. 10.1097/01.shk.0000209540.99176.72, 16721263.
34. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, Sato Y, Hiraga N, Adachi N, Yoshino T, Nishibori M. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007, 21:3904-3916. 10.1096/fj.07-8770com, 17628015.
35. Graham SH, Chen J. Programmed cell death in cerebral ischemia. J Cereb Blood Flow Metab 2001, 21:99-109.
36. Jiang W, Bell CW, Pisetsky DS. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J Immunol 2007, 178:6495-6503.
37. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006, 203:1637-1642. 10.1084/jem.20052203, 2118346, 16818669.